Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

Fig. 2

Effect of BRCA1 and BRCA2 siRNA on androgen-independent prostate cancer cells. A and B. Effect of siRNA on BRCA1 and BRCA2 expression in PC-3 and LNCaP-LA cells. Mock transfected cells (M) or cells transfected with BRCA1 (B1) or BRCA2 (B2) siRNA or negative control siRNA (N) were incubated for 48 h before harvesting for real-time polymerase chain reaction (A) and western blotting (B). Values are expressed as means ± standard deviations (SD) (n = 3). **P < 0.01 vs. negative (N). C Following transfection, PC-3, and LNCaP-LA cells were incubated in the medium. After 48 h, the cells were cultured in a medium with or without olaparib (10 µM). After 72 h (PC-3 cells) and 96 h (LNCaP-LA cells), the number of viable cells was evaluated using an MTS assay. Values are expressed as mean ± SD (n = 4). *p < 0.05. Ola; olaparib

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us